Derma Sciences Inc  

(Public, NASDAQ:DSCI)   Watch this stock  
Find more results for DSCI
-0.26 (-2.64%)
Apr 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 9.47 - 9.90
52 week 9.25 - 15.51
Open 9.87
Vol / Avg. 103,187.00/166,872.00
Mkt cap 241.34M
P/E     -
Div/yield     -
EPS -1.41
Shares 25.14M
Beta 1.10
Inst. own 57%
May 30, 2014
Derma Sciences, Inc. at Podiatric Residency Education Summit West Add to calendar
May 26, 2014
Derma Sciences, Inc. at American Pediatric Surgical Nurses Association Conference Add to calendar
May 20, 2014
Derma Sciences, Inc. Annual Shareholder Meeting - 3:00PM EDT - Add to calendar
May 20, 2014
Derma Sciences, Inc. at Amerinet Conference Add to calendar
May 12, 2014
Q1 2014 Derma Sciences, Inc. Earnings Release (Estimated) Add to calendar
May 5, 2014
Derma Sciences, Inc. at the Spring Hospital/Pharmacy Conference Add to calendar
May 1, 2014
Derma Sciences, Inc. at Oncology Nursing Conference Add to calendar
Apr 24, 2014
Derma Sciences, Inc. at Advanced Wound Care Conference
Apr 7, 2014
Derma Sciences, Inc. at IDN Summit & Expo - Spring
Apr 2, 2014
Derma Sciences, Inc. at MedAssets Healthcare Business Summit
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -26.22% -30.06%
Operating margin -24.50% -30.10%
EBITD margin - -25.43%
Return on average assets -23.84% -24.91%
Return on average equity -27.27% -28.05%
Employees 258 -
CDP Score - -


United States - Map
+1-609-5144744 (Phone)
+1-302-6554620 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Derma Sciences, Inc. (Derma Sciences), is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care, advanced wound care and traditional wound care products. pharmaceutical wound care, advanced specialty medical device/pharmaceutical company with a primary focus on wound care. The Company has one pharmaceutical wound care product candidate that has completed a Phase 2 study and is working towards initiation of a Phase 3 study in 2012. The majority of its products are sold through distributors to various health care providers such as wound care centers, extended care facilities, acute care facilities, home health care agencies and physicians� offices. Some of its products are sold through retail channels. Effective September 4, 2013, Derma Sciences Inc acquired a 7.3% stake in Comvita Ltd, a manufacturer and wholesaler of natural health products.

Officers and directors

Edward J. Quilty Chairman of the Board, President, Chief Executive Officer
Age: 62
Bio & Compensation  - Reuters
John E. Yetter CPA Chief Financial Officer, Executive Vice President - Finance
Age: 60
Bio & Compensation  - Reuters
Robert C. Cole Group President - Traditional Wound Care and Corporate Accounts
Age: 60
Bio & Compensation  - Reuters
Barry J. Wolfenson Group President - Advanced Wound Care and Pharmaceutical Development
Age: 46
Bio & Compensation  - Reuters
Frederic Eigner Executive Vice President - Operations; General Manager of Derma Sciences Canada, Inc.
Age: 63
Bio & Compensation  - Reuters
Bruce F. Wesson Vice Independent Lead Director
Age: 70
Bio & Compensation  - Reuters
Stephen T. Wills CPA Lead Independent Director
Age: 56
Bio & Compensation  - Reuters
Amy S. Paul Director
Bio & Compensation  - Reuters
Srini Conjeevaram Independent Director
Age: 54
Bio & Compensation  - Reuters
Brett D. Hewlett Independent Director
Age: 50
Bio & Compensation  - Reuters